%D9%85%D8%B9%D9%87%D8%AF_%D8%AF%D8%A7%D9%86%D8%A7-%D9%81%D8%A7%D8%B1%D8%A8%D8%B1_%D9%84%D9%84%D8%B3%D8%B1%D8%B7%D8%A7%D9%86Category:Dana-Farber_Cancer_InstituteDana-Farber_Cancer_InstituteDana%E2%80%93Farber_Cancer_Institute%E3%83%80%E3%83%8A%E3%83%BB%E3%83%95%E3%82%A1%E3%83%BC%E3%83%90%E3%83%BC%E7%99%8C%E7%A0%94%E7%A9%B6%E6%89%80Q1159198
about
Maria Ciemerych-LitwinienkoMyles BrownLear BraceFranziska MichorShunmin HeMarco ColonnaPascal BraunJorge CastilloRonny DrapkinBrian J. DrukerMarcela V MausHaribabu ArthanariAndrew L. KungYang LiuZhen ShaoAntonio SaccoChensheng ZhouStephen P. FinnMarkus G. SeidelZijing LiuPhilippe VaglioNicolas BertinKathrin M. BerntIngrid PaineHaopeng XiaoCarl R WalkleyJerome RitzRavi Kumar GuttiJudith BalmañaSébastien VigneauWilliam M. ShihBaochun ZhangJasper E NeggersChenqi XuJia ZhouDavid P. SteensmaJonathan WilliamsEric S. FischerFrancisco M. MartyQiang Chen
P108
Melatonin versus Placebo in Breast CancerCombination Chemotherapy in Treating Patients With Advanced Colorectal CancerImmunotherapy Study for Surgically Resected Pancreatic CancerDinutuximab in Combination With Sargramostim in Treating Patients With Recurrent OsteosarcomaA Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal CarcinomaTrial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal CancerStudy of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell CarcinomaDurvalumab, Tremelimumab + Radiotherapy in Gynecologic CancerWindow Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral CavityStudy Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPCProstvac in Patients With Biochemically Recurrent Prostate CancerNivolumab Plus Ipilimumab in Thyroid CancerAdjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and NeckBiomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLCLosartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic CancerEpstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal CarcinomaPembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid TumorsA Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or ImmunotherapyAdjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast CancerOlaparib With or Without Atezolizumab in Treating Patients With Locally Advanced or Metastatic Non-HER2-Positive Breast CancerA Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive GlioblastomaCombination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch RepairCombination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal CancerA Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast CancerA Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast CancerPhase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BCTargeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHNRibociclib + PDR001 in Breast Cancer and Ovarian CancerADAPT-BLADDER: Modern Immunotherpy in BCG-Relapsing Urothelial Carcinoma of the BladderPVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast CancerProvenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone TherapyA Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast CancerA Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin LymphomaCombination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaTrial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain TumorsPomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple MyelomaThe Young Women's Breast Cancer StudyA Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients
P6153
Melatonin versus Placebo in Breast CancerStudy of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic AdenocarcinomaThe Young Women's Breast Cancer StudyA Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer PatientsWhole-Exome Sequencing (WES) of Cancer PatientsAdvance Care Planning: Promoting Effective and Aligned Communication in the ElderlyNiraparib in Patients With Pancreatic CancerA Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2A Pilot Weight Control Intervention at HPHCA Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) TumorsZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast CancerCampath in Chronic GVHDProcurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical TrialsVaccination for the Treatment of Previously Untreated or Relapsed Follicular LymphomaNatural History Study of Patients With Chronic Myelogenous LeukemiaGM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid MalignanciesPemetrexed in Patients With Advanced Neuroendocrine TumorsImatinib in Patients With Mucosal or Acral/Lentiginous MelanomaCombination Bortezomib and Rituximab in Patients With Waldenstrom's MacroglobulinemiaPerifosine in Patients With Relapsed/Refractory Waldenstrom's MacroglobulinemiaOxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian CarcinomaBortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell TransplantationPyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPanobinostat (LBH589) in Patients With Metastatic MelanomaEffects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in VitroCarfilzomib, Rituximab and Dexamethasone in Waldenstrom's MacroglobulinemiaSocialization of Adult Men With Congenital Hemophilia A or BCabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid TumorsOfatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLLTivozanib As Maintenance Therapy In GYNA Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple MyelomaAdoptive Transfer of MART1/Melan-A CTL for Malignant MelanomaPhase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric CancerDevelopment of a Positive Psychology Intervention to Improve Mood and HRQoL in Patients Post-HSCT - Proof of ConceptA Randomized Phase III Study - Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADTA Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast CancerTesting Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain GoalsSmartphone Technology to Alleviate Malignant Pain (STAMP)Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
P859
Q16574722-DE420C63-B449-4750-8554-7860BF812774Q30347463-D7CC4725-A421-4625-87BC-9521DC92772AQ30503936-d901fea0-4665-7f0f-a391-9aae52ec0789Q33177805-f239ff21-4bb7-f8e4-db2e-53237151e8f9Q37372867-E1B64C57-418E-434C-A3AC-AA986ADCA3F6Q37377244-14757737-6EEF-4DBC-A06A-61D2874C7B0FQ37379763-71B35437-68FB-48BC-9EFF-E20084F8EACAQ37379763-DE407CE1-D078-4BFE-AFD0-5A1AC04BF954Q37838479-6AE98CC9-9BA2-4D5E-8BE5-4BC62F3EC1DDQ37843472-7D1B0B66-6C2C-454F-AA93-A9A8881D27D6Q38154974-6C796897-0D65-4129-A320-2CEF1B70974FQ38321614-184c1e8a-47cc-8423-c88b-4dcad745d2e1Q38359784-57C101F0-A0B0-41DF-B695-FFCAB13003DCQ38544548-2C135959-2A12-42DF-886C-653A4FF861C9Q39051368-30374F06-E15E-49A7-9BC4-FEF4BA692BE2Q39187693-B55F50F4-66A3-407B-8F06-E645D5A63B89Q40001595-F8253DD7-D823-498C-98FB-5CF906534351Q40058385-3D74F505-9CDE-4009-835A-BB27C5D0AC81Q40115968-38D16916-A0FF-4559-8B03-B973C45ACF05Q40137985-7EA20BEE-C9EF-4DC6-B10F-60E48AB6F453Q40183993-77B7EAD5-1C6F-42F5-9B3D-EBF767149991Q40584176-C6176771-D9A6-45F9-9D72-733F6FBD6889Q40584212-82E2405F-1ACB-44BC-A116-F50293A339D7Q40619894-D304387F-F1CB-4C7F-B926-5356E625E7B6Q41044874-4857396B-F33F-45D7-B577-AE09424BC76AQ41137952-EADDF585-6C42-47DA-ACC4-58991A3BB723Q41175729-C745BE6A-F20B-4E63-A959-6B35D7700CB1Q41590860-AB068363-0328-4109-ADD6-3D0915663F05Q41652432-424732CC-2E22-4384-AC30-D8B9E4F2A0D5Q41839999-92697F36-BA2C-4F65-9CB0-D7CD6931F0A4Q41851002-8C3D26DF-EA6D-4890-B40F-4DC236CE561FQ41870196-16e26938-4e39-78e9-c8a2-be0b5cc5b21eQ41886707-816E1FA7-EE87-4258-9357-1B92956EACB8Q42175315-560FCA1A-B274-45E9-BA37-9B0664223584Q42404302-A6EA9A1A-9C0A-4654-B4FA-EA8817EAD961Q42552991-0D708934-EA79-4024-B152-779278998F28Q42586417-02CC521C-543B-42E0-8708-916035E2AE62Q42883899-6CEFCEC3-93A7-49C4-B44F-EB3F4B13D745Q43073160-114C490F-F0F9-42A3-B665-576FC89A40D3Q43126104-EF29073C-D08D-479E-B31B-D36A337FACC3
P108
description
Krankenhaus
@de
griya sakit
@jv
hospital d'Estaos Xuníos
@ast
hospital in Massachusetts, United States
@en
institut américain
@fr
rumah sakik
@min
rumah sakit di Amerika Serikat
@id
rumoh sakét
@ace
ziekenhuis in de Verenigde Staten
@nl
בית חולים בארצות הברית
@he
name
Dana-Farber Cancer Institute
@de
Dana-Farber Cancer Institute
@fr
Dana–Farber Cancer Institute
@en
מכון דנה-פרבר לסרטן
@he
معهد دانا-فاربر للسرطان
@ar
ダナ・ファーバー癌研究所
@ja
丹那-法博癌症研究所
@zh
type
label
Dana-Farber Cancer Institute
@de
Dana-Farber Cancer Institute
@fr
Dana–Farber Cancer Institute
@en
מכון דנה-פרבר לסרטן
@he
معهد دانا-فاربر للسرطان
@ar
ダナ・ファーバー癌研究所
@ja
丹那-法博癌症研究所
@zh
altLabel
Dana-Farber Cancer Institute
@en
ダナファーバーがん研究所
@ja
達納-法伯癌症研究院
@zh
prefLabel
Dana-Farber Cancer Institute
@de
Dana-Farber Cancer Institute
@fr
Dana–Farber Cancer Institute
@en
מכון דנה-פרבר לסרטן
@he
معهد دانا-فاربر للسرطان
@ar
ダナ・ファーバー癌研究所
@ja
丹那-法博癌症研究所
@zh
P1278
P1566
P214
P244
P268
P269
P3153
P646
P1278
549300CLSX1WQ2279M82
P1297
04-2263040
P131
P1566
P18
P213
0000 0001 2106 9910
P2139
1.495.111.225